Pathways’ Picks February 3: Novel Device Growth, CED Under Review, and Global Updates

article image

In this week’s roundup: A recovery in FDA novel device approvals in 2020; CMS’ coverage-with-evidence-development policy is under legal review; AdvaMed criticizes EU’s vaccine export controls; Australia cancels COVID-era ventilator and face mask policies; Sen. Warren moves to Finance Committee, and key personnel moves at CMS and FDA.

The legality of CMS’ coverage-with-evidence-development (CED) program is under review at HHS but may be getting new life. FDA is touting record-breaking novel device numbers in 2020, including non-COVID-19 and COVID-19 technology. Also in this week’s Pathways’ Picks: news from Europe, Australia, and Capitol Hill.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: